Lisavanbulin

N/A

Report date: 2024/06/28 13:29:50
NME

Base Information

Drug NameLisavanbulin
Drug Alias NameBAL-101553BAL-27862B-553
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsApoptosis stimulantsVascular disrupting agents (VDA)
TargetsTubulin
Therapy Area/IndicationsSolid tumoursGlioblastomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesGermany +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBasilea Pharmaceutica
China Registration ClassN/A

Develop Information

Active CompaniesGlioblastoma Foundation IncBasilea Pharmaceutica
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsSolid tumoursGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A